SponsoredContent

Despite innovative treatments for chronic spontaneous urticaria (CSU), gaps in access and prescribing variations persist. Analysis Group’s real-world evidence analysis of a large US insurance claims database reveals significant disparities in healthcare utilization and a concerning reliance on systemic corticosteroids and emergency services. Explore their findings to understand how variations in advanced therapy access impact CSU management and identify opportunities to improve patient outcomes.

Leveraging RWE to Assess CSU